The trial will involve both single and multiple-ascending doses of SUDO-550 being given to healthy volunteers.

InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to severe plaque psoriasis.

Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 ...

Published in Nature Neuroscience, the study suggests that partially restraining TYK2 could be a strategy to reduce tau levels and toxicity. “Many studies have shown that the accumulation of tau ...

As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of ...

Takeda is chasing down what is predicted to be a sizeable market for TYK2 drugs in inflammatory ... which work at different targets in the same pathway. BMS has previously said it reckons Sotyktu ...

Published in Nature Neuroscience, the study suggests that partially restraining TYK2 could be a strategy to reduce tau levels and toxicity. Previous studies showed that tau is chemically modified ...

Published in Nature Neuroscience, the study suggests that partially restraining TYK2 could be a strategy to reduce tau levels and toxicity. "Many studies have shown that the accumulation of tau in ...